Oxygenta Pharmaceutical (524636) Q3 2026 earnings summary

Executive summary

• Board approved unaudited financial results for the quarter and nine months ended 31 December 2025.

• Limited review report by statutory auditors presented and accepted.

• Internal Complaints Committee reconstituted effective 4 February 2026.

Financial highlights

• Total income for Q3 FY26 was ₹3,393.09 lakhs, up from ₹3,320.61 lakhs in Q3 FY25.

• Net loss for Q3 FY26 stood at ₹484.30 lakhs, compared to a net loss of ₹392.82 lakhs in Q3 FY25.

• For the nine months ended 31 December 2025, total income was ₹10,929.86 lakhs and net loss was ₹1,591.42 lakhs.

• Basic and diluted EPS for Q3 FY26 was (₹1.32), compared to (₹1.07) in Q3 FY25.

Key financial ratios and metrics

• Gross margin and EBITDA not explicitly stated; operating loss before tax for Q3 FY26 was ₹632.65 lakhs.

• Paid-up equity share capital remained at ₹3,698.35 lakhs.